PGWD: Integrating Personal Genome for Warfarin Dosing
- 193 Downloads
Warfarin is a drug normally used in the prevention of thrombosis and the formation of blood clots. The dosage of warfarin is strongly affected by genetic variants of CYP2C9 and VKORC1 genes. Current technologies for detecting the variants of these genes are mainly based on real-time PCR. In recent years, due to the rapidly dropping cost of whole genome sequencing and genotyping, more and more people get their whole genome sequenced or genotyped. However, current software for warfarin dosing prediction is based on low-throughput genetic information from either real-time PCR or melting curve methods. There is no bioinformatics tool available that can take the high-throughput genome sequencing data as input and determine the accurate dosage of warfarin. Here, we present PGWD, a web tool that analyzes personal genome sequencing data and integrates with clinical information for warfarin dosing.
KeywordsWarfarin Dosage Pharmacogenomics Genome interpretation
This research is supported by the National Natural Science Foundation of China (Grant No. 31200688).
- 2.Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 348(9025):423–428PubMedCrossRefGoogle Scholar
- 7.Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7):2329–2333. doi: 10.1182/blood-2005-03-1108 PubMedCrossRefGoogle Scholar